Aditya Bardia, MD, MPH, on HR-Positive, HER2-Negative Advanced Breast Cancer: New Findings on Datopotamab Deruxtecan vs Chemotherapy
2023 SABCS
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses updated phase III results from the TROPION-Breast01 study. The data showed an improvement in progression-free survival with datopotamab deruxtecan compared with investigator’s choice of chemotherapy across all subgroups of patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received one to two prior lines of chemotherapy (Abstract GS02-01).
The ASCO Post Staff
Barbara Pistilli, MD, of France’s Gustave Roussy, discusses a phase Ib analysis from the CAPItello-292 study, which showed capivasertib plus palbociclib plus fulvestrant was tolerable at all dose levels in heavily pretreated patients with hormone receptor–positive, HER2-negative advanced breast cancer. As data collection continues, evidence of clinical activity has been observed in patients treated with the recommended phase III dose (Abstract PS12-09).
The ASCO Post Staff
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates with the addition of nivolumab to neoadjuvant chemotherapy (Abstract GS01-01).
The ASCO Post Staff
Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score and its use in patients with intermediate/high DCIS scores (Abstract GS03-01).
The ASCO Post Staff
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient-reported outcomes from the phase III CAPItello-291 study; the trial centered on adding capivasertib to fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer. Patients treated with capivasertib and fulvestrant reported maintained health-related quality of life longer than those treated with placebo and fulvestrant (Abstract PS02-02).
The ASCO Post Staff
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses data from the phase II KEYLYNK-009 study, which compared pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (Abstract GS01-05).
